Hyperphosphorylated Tau, Increased Adenylate Cyclase 5 (ADCY5) Immunoreactivity, but No Neuronal Loss in ADCY5‐Dyskinesia. Issue 1 (14th December 2019)

• Record Type: Journal Article
• Authors: Chen, Dong‐Hui; Latimer, Caitlin S.; Spencer, Min; Karna, Prasanthi; Gonzalez‐Cuyar, Luis F.; Davis, Marie Y.; Keene, C. Dirk; Bird, Thomas D.; Raskind, Wendy H.
• Is Part Of: Movement disorders clinical practice. Volume 7:Issue 1(2020)
• Page Start: 70
• Page End: 77
• Publication Date: 2019-12-14
• Subjects: ADCY5‐dyskinesia -- tau -- neurogenetics -- neuropathology; Movement Disorders; Movement disorders -- Periodicals; Movement disorders; Periodicals; Periodicals; 616
• DOI: 10.1002/mdc3.12873
• Languages: English
• ISSNs: 2330-1619

Abstract

ABSTRACT: Background: Adenylate cyclase 5 (ADCY5)‐related dyskinesia is a childhood‐onset movement disorder. Manifestations vary in frequency and severity and may include chorea, tremor, dystonia, facial twitches, myoclonus, axial hypotonia, and limb hypertonia. Psychosis is likely part of the broader spectrum. ADCY5 is widely expressed in the brain, especially in the striatum. Previous reports of brain autopsies of 2 subjects with likely ADCY5‐dyskinesia were limited by the absence of a molecular diagnosis. In 1 case, normal gross pathology was reported. In the other case, ADCY5 expression was not examined and neuropathological findings were confounded by age and comorbidities. Objectives: To examine ADCY5 expression and neuropathological changes in ADCY5‐dyskinesia. Methods: An extensive brain autopsy, including immunohistochemical analyses with antibodies to paired helical filament tau, α‐synuclein, amyloid‐β, microtubule‐associated protein 2, and ADCY5, was performed. Results: The patient, with a p.M1029K ADCY5 variant, had severe dyskinesias from early childhood, later recurrent episodes of psychosis, and died at age 46. Gross pathology was unremarkable, but we detected increased immunoreactivity for ADCY5 in neurons in multiple brain regions. Despite no history of brain trauma to suggest chronic traumatic encephalopathy, we found tau deposits in the deep cortical sulci, midbrain, and hippocampus with minimal amyloid pathology and no Lewy bodies. Conclusions: We present the first brain autopsy findings in a molecularly proven case of ADCY5‐dyskinesia, showing increased ADCY5 immunoreactivity in neurons and evidence of tau deposition. Additional patients will need to be studied to determine whether increased immunoreactivity for ADCY5 is a signature for ADCY5‐dyskinesia and whether this disease has a tauopathy component.